Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

AFFYMETRIX/MOLECULAR DYNAMICS MICROCHIP-BASED DNA DIAGNOSTIC DEVICE

This article was originally published in The Gray Sheet

  • News

Executive Summary

AFFYMETRIX/MOLECULAR DYNAMICS MICROCHIP-BASED DNA DIAGNOSTIC DEVICE will be developed first for use in detecting drug-resistant strains of HIV, Affymetrix said Oct. 24. The joint venture partners have received a cooperative $31.5 mil., five-year grant from the National Institute of Standards and Technology's (NIST) Advanced Technology Program (ATP) to develop miniaturized integrated nucleic acid diagnostic (MIND) devices and readers (MIND Readers) "suitable for the rapid and cost effective diagnosis of a wide variety of diseases in a hospital, clinic or doctor's office setting," Affymetrix explained.

Table

View full table

Tags:
Latest Headlines

News We're Watching: LDT Final Rule Near Publication, Zimmer ROSA Used In Shoulder Surgery, $60M For Menopause Clinic

Epitel Gets 510(k) Clearance On Remote EEG Technology

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

See All
UsernamePublicRestriction

Register

MT002987

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By